In conclusion, we showed that triplet therapy with afatinib, cetuximab, and bevacizumab repeatedly induced pathological CR in lung cancers harboring EGFR T790M mutations with tolerable toxicity in preclinical xenograft models. This evidence concerns the gene EGFR and lung cancer.